10:25:28 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-30 Kvartalsrapport 2024-Q2
2024-05-27 Ordinarie utdelning OBSRV 0.00 NOK
2024-05-24 Årsstämma 2024
2024-03-13 Bokslutskommuniké 2023
2023-11-22 Extra Bolagsstämma 2023
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-30 Ordinarie utdelning OBSRV 0.00 NOK
2023-05-26 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-03 Årsstämma 2022
2022-06-03 Kvartalsrapport 2022-Q1
2022-06-03 Ordinarie utdelning OBSRV 0.00 NOK
2022-03-29 Bokslutskommuniké 2021
2022-02-04 Extra Bolagsstämma 2022
2021-11-03 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-25 Ordinarie utdelning OBSRV 0.00 NOK
2021-05-21 Årsstämma 2021
2021-05-12 Kvartalsrapport 2021-Q1
2021-02-23 Bokslutskommuniké 2020
2020-11-03 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning OBSRV 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-16 Extra Bolagsstämma 2020
2020-05-12 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019

Beskrivning

LandNorge
ListaOAX Equities
SektorHälsovård
IndustriMedicinteknik
Observe Medical är ett norskt bolag verksamma inom medicinteknik. Bolaget bedriver utveckling av tekniska instrument som används inom intensivvården. Produkterna säljs under olika varumärken och är särskilt specialiserade för urinmätning. Störst verksamhet återfinns inom den nordiska samt europeiska marknaden. Bolaget kom till som en avknoppning från Navamedic och har sitt huvudkontor i Oslo, Norge.
2023-02-17 07:01:00

Observe Medical ASA: Fourth quarter 2022 results

Oslo, 17 February 2023 - Observe Medical ASA ("the Company" or "Observe Medical") today releases its results for the fourth quarter of  2022.

"The year 2022 has been a transformational year for Observe Medical. Building on the growth initiatives seen earlier in the year, we signed two exclusivity agreements in the fourth quarter to acquire a market leading product portfolio of urine measurement systems and a medical production facility in Italy. It has been an exciting final quarter and looking ahead, our roadmap is clear - we are working towards becoming Europe's leading urine measurement provider. As we enter 2023, I look forward to keeping the market updated on our transactions and several workstreams," said Rune Nystad, CEO of Observe Medical.

Portfolio update

In the fourth quarter, the company continued to progress its partnership with Fresenius Kabi in the US. Since the start of the partnership, Observe Medical has provided Fresenius with Biim devices and training across 265 dialysis clinics. As part of a recent and significant reorganisation, Fresenius has re-confirmed that Biim will be central to their dialysis offering moving forward.

In the same quarter, Observe Medical announced an exclusivity agreement with Ferrari L., a medical device production facility in Verona, Italy. Once the deal is completed, Observe Medical plans to manufacture most of its own products in-house. This will allow the company to control its value chain, significantly optimise the costs of goods sold, and improve profitability.

Observe has also commenced the production set-up of the urine measurement portfolio it intends to acquire from Convatec and is ready to start producing the tools needed to make individual medical device components. Once production is initiated, Sippi® will be introduced to the market via the same established sales channels as Unometer™ and AdboPressure™.

At the start of 2023, Observe Medical appointed Jørgen Mann as the company's Chief Commercial Officer. He will lead Observe Medical's commercial efforts as the company reaches new markets.
 

Financial highlights

In the fourth quarter of 2022, Observe Medical reported NOK 4.1 million in operating revenues, compared to NOK 3.6 million in the fourth quarter of 2021. For 2022, the company's operating revenues amounted to NOK 19.5 million compared to NOK 24 million in 2021.

For the fourth quarter of 2022, the company's reported NOK 4.1 million in operating revenue compared to NOK 3.6 million in the same quarter in 2021. Operating revenue for the full year of 2022 amounted to NOK 19.5 million compared to NOK 24.0 in 2021. The company's EBITDA for the quarter amounted to NOK -16.5, compared to NOK -14.1 in the fourth quarter 2021.  For the full year of 2022, the company's EBITDA amounted to NOK -53.4 million compared to NOK -42.6 million in 2021. The result reflects continues investments in growth inititaives and consolidation of Biim Ultrasound from March 1, 2022.

Financing

As announced on the 14[th] of December 2022, the company is working to raise funds to support the acquisitions of the Unometer™ product portfolio and Ferrari L. The company will consider the most beneficial financial structure to support the transactions based on today's capital market. No definitive decision has been made, and no binding agreements regarding the completion of these transactions have been entered.  

Management will host a presentation and Q&A session at 08:30 CET today. The presentation will take place at Haakon VIIs gate 2 and will be available via webcast at the following link: https://channel.royalcast.com/landingpage/hegnarmedia/20230217_3/

See the attached presentation material for more detailed information about the financial results for the fourth quarter and full year of 2022.

The presentation and recording will be made available under the Investor Relations section on the Company's website, https://observemedical.com/investor-relations/.

For further information, please contact:
 

Rune Nystad, CEO Observe Medical
Mobile: +47 916 24 683
E-mail: rune.nystad@observemedical.com

Per Arne Nygård, CFO of Observe Medical
Mobile: +47 411 04 345
E-mail: perarne.nygard@observemedical.com

About Observe Medical
 

Observe Medical is a Nordic medtech company that develops, markets and sells  innovative medtech products for the global market. The Company is committed to improving patient welfare and patient outcomes, improving clinical data accuracy and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and commercialisation of its broad portfolio of medical technology products, mainly

in urine measurement, ultrasound, anesthesiology/ICUs, surgery and wound care, in combination with targeted M&A. The Company is headquartered in Oslo, Norway, with additional offices in Narvik (Norway), Gothenburg (Sweden), Oulu (Finland), and Seattle (the US). In addition, Observe Medical has a direct sale organisation in the Nordics and a distributor network internationally.

Further information is available at www.observemedical.com.